Individuals with predominantly classic (>50% of lesion area on fluorescein angiography), sub-foveal CNV not previously treated with PDT or antiangiogenic drugs were included. The need for PDT (active or sham) was determined every 3 months using fluorescein angiography. Patients in the PDT group received a mean of 19.2 sham injections, and ranibizumab groups received a mean of 2.2 and 1.9 sham PDT interventions, respectively. Change in lesion characteristics on angiography also favoured ranibizumab. In pooled ranibizumab groups, 3 of 277 patients (1.1%) developed endophthalmitis at a rate of 0.05% per injection.
CNV – choroidal neovascularisation; PDT – photodynamic therapy; VEGF – vascular endothelial growth factor; BCVA – best corrected visual acuity; ns – not significant; AMD – age-related macular degeneration.
Reference: Brown DM et al, “Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study” Ophthalmology 2009;116:57–65
Funding
Medical Research Council UK (MR/R000735/1).
Competing interests
The authors declare no competing interests.
Footnotes
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Please note that the infographic is best viewed online.